Lasho TL - Search Results

1

Isolated del(5q) in myeloid malignancies: clinicopathologic and molecular features in 143 consecutive patients.

Patnaik MM, Lasho TL, Finke CM, Knudson RA, Ketterling RP, Chen D, Hoyer JD, Hanson CA, Tefferi A. Patnaik MM, et al. Among authors: lasho tl. Am J Hematol. 2011 May;86(5):393-8. doi: 10.1002/ajh.21984. Am J Hematol. 2011. PMID: 21523797 Free article.

2

Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia.

Tefferi A, Lasho TL, Wolanskyj AP, Mesa RA. Tefferi A, et al. Among authors: lasho tl. Blood. 2004 May 1;103(9):3547-8. doi: 10.1182/blood-2003-10-3505. Epub 2003 Dec 30. Blood. 2004. PMID: 14701686 Free article.

3

FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia.

Pardanani A, Brockman SR, Paternoster SF, Flynn HC, Ketterling RP, Lasho TL, Ho CL, Li CY, Dewald GW, Tefferi A. Pardanani A, et al. Among authors: lasho tl. Blood. 2004 Nov 15;104(10):3038-45. doi: 10.1182/blood-2004-03-0787. Epub 2004 Jul 29. Blood. 2004. PMID: 15284118 Free article.

4

Platelet-rich plasma serotonin levels in chronic myeloproliferative disorders: evaluation of diagnostic use and comparison with the neutrophil PRV-1 assay.

Koch CA, Lasho TL, Tefferi A. Koch CA, et al. Among authors: lasho tl. Br J Haematol. 2004 Oct;127(1):34-9. doi: 10.1111/j.1365-2141.2004.05149.x. Br J Haematol. 2004. PMID: 15384975 Free article.

5

WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature.

Elliott MA, Hanson CA, Dewald GW, Smoley SA, Lasho TL, Tefferi A. Elliott MA, et al. Among authors: lasho tl. Leukemia. 2005 Feb;19(2):313-7. doi: 10.1038/sj.leu.2403562. Leukemia. 2005. PMID: 15549147 No abstract available.

6

Neutrophil polycythemia rubra vera-1 expression in classic and atypical myeloproliferative disorders and laboratory correlates.

Sirhan S, Lasho TL, Elliott MA, Tefferi A. Sirhan S, et al. Among authors: lasho tl. Haematologica. 2005 Mar;90(3):406-8. Haematologica. 2005. PMID: 15749676

7

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.

Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, Gilliland DG, Tefferi A. Steensma DP, et al. Among authors: lasho tl. Blood. 2005 Aug 15;106(4):1207-9. doi: 10.1182/blood-2005-03-1183. Epub 2005 Apr 28. Blood. 2005. PMID: 15860661 Free PMC article.

8

Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2(V617F) in granulocytes.

Lasho TL, Mesa R, Gilliland DG, Tefferi A. Lasho TL, et al. Br J Haematol. 2005 Sep;130(5):797-9. doi: 10.1111/j.1365-2141.2005.05682.x. Br J Haematol. 2005. PMID: 16115143 Free article. No abstract available.

9

JAK2 mutations in myeloproliferative disorders.

Tefferi A, Lasho TL, Gilliland G. Tefferi A, et al. Among authors: lasho tl. N Engl J Med. 2005 Sep 29;353(13):1416-7; author reply 1416-7. doi: 10.1056/NEJMc051878. N Engl J Med. 2005. PMID: 16192494 No abstract available.

10

Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia.

Tefferi A, Sirhan S, Lasho TL, Schwager SM, Li CY, Dingli D, Wolanskyj AP, Steensma DP, Mesa R, Gilliland DG. Tefferi A, et al. Among authors: lasho tl. Br J Haematol. 2005 Oct;131(2):166-71. doi: 10.1111/j.1365-2141.2005.05743.x. Br J Haematol. 2005. PMID: 16197445 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

219 results

Search Page

Filters